Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human imatinib-sensitive and imatinib-resistant cells compared in the absence of imatinib
Both imatinib-sensitive and imatinib-resistant cells were compared in the absence of imatinib. The resistant cells in the presence of imatinib were compared to the sample in the absence of imatinib. The sample from the resistant cells in the presence of imatinib was labelled in duplicate to assess f...
ORGANISM(S): Homo sapiens 
2003-11-30 | E-MEXP-21 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of CD34 positive mononuclear cells from drug naive, chronic myeloid leukemia (CML) patients to determine an expression signature predictive of a major cytogenic response in CML patients treated with Imatinib.
Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may ben...
ORGANISM(S): Homo sapiens 
2009-12-31 | E-GEOD-14671 | biostudies-arrayexpress
UnknownEffect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC4979167 | biostudies-literature
Sort   by:  
 Page size